TradeFlare's AI research teams analysed BCYC on 9 market nights between April 27, 2026 and May 8, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| May 8, 2026 | HOLD | $4.89 | — / — | -7.5% | -14.6% | Successful clinical trial results for BT8009. |
| May 7, 2026 | BUY | $5.15 | — / — | -4.5% | -14.1% | Successful clinical trial results for pipeline drug candidates. |
| May 6, 2026 | BUY | $4.90 | — / — | -8.0% | -17.1% | Positive clinical trial data for lead drug candidates. |
| May 5, 2026 | BUY | $4.94 | — / — | -3.7% | -14.3% | The 8-K filing regarding workforce reduction could signal a strategic shift or cost-cutting measures that may improve future profitability. |
| May 4, 2026 | HOLD | $4.80 | — / — | -4.9% | -13.0% | Successful clinical trial results for key drug candidates. |
| April 30, 2026 | BUY | $4.73 | — / — | +3.6% | -0.6% | Workforce reduction announcement could signal improved cost discipline. |
| April 29, 2026 | BUY | $4.69 | — / — | +8.9% | -1.3% | Workforce reduction announcement may signal cost discipline and potential margin expansion. |
| April 28, 2026 | HOLD | $4.77 | — / — | +4.5% | -2.6% | Workforce reduction announcement may signal cost-saving measures. |
| April 27, 2026 | BUY | $4.84 | — / — | +3.6% | -4.2% | The 8-K filing regarding workforce reduction could signal improved cost management and potential margin expansion. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.